Barclays’s Ultragenyx Pharmaceutical RARE Stock Holding History

Barclays’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,500	Closed	-$453K	–	5483
2025 Q1	$453K	Buy	+12,500	New	+$520K	﹤0.01%	3593
2024 Q2	–	Sell	-30,000	Closed	-$1.4M	–	5217
2024 Q1	$1.4M	Hold	30,000	–	–	﹤0.01%	2863
2023 Q4	$1.43M	Buy	+30,000	New	+$1.16M	﹤0.01%	3173
2019 Q2	–	Sell	-600	Closed	-$42K	–	7209
2019 Q1	$42K	Hold	600	–	–	﹤0.01%	6003
2018 Q4	$26K	Buy	+600	New	+$32.8K	﹤0.01%	5782
2017 Q4	–	Sell	-100	Closed	-$5K	–	7073
2017 Q3	$5K	Sell	100 -400	-80%	-$23.7K	﹤0.01%	6423
2017 Q2	$31K	Hold	500	–	–	﹤0.01%	5594
2017 Q1	$34K	Buy	+500	New	+$38.1K	﹤0.01%	5551
2015 Q3	–	Sell	-25,000	Closed	-$2.55M	–	7004
2015 Q2	$2.55M	Buy	+25,000	New	+$1.94M	﹤0.01%	2027

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Barclays's RARE Position: Q2 2026 in Review

Barclays reduced its Ultragenyx Pharmaceutical (RARE) stake by 38% in Q2 2026, selling an estimated $2.36M and leaving 154,876 shares worth $5.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1826.

Barclays first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. The position peaked at $12.8M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Barclays held 154,876 shares of Ultragenyx Pharmaceutical worth $5.17M as of Q2 2026.
Barclays sold 94,931 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $2.36M.
Ultragenyx Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1826 holding.
Barclays first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
Barclays's Ultragenyx Pharmaceutical position peaked at $12.8M in Q3 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.